COCP READ THE FULL COCP RESEARCH REPORT Business Update Norovirus Challenge Study to Commence in 4Q25 Cocrystal Pharma, Inc. ...

“The absence of any approved norovirus treatments or vaccines creates a substantial market opportunity for Cocrystal,” said James Martin, Cocrystal's CFO and co-CEO. “ With 685 million global cases ...

Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and ...

President Trump Is Targeting Big Pharma With Tariffs Pharma stocks like Novo Nordisk and Pfizer have dropped amid trade war risks.

About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza ...

All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well toleratedCompany expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this ...

The cocrystal strategy holds promise in enhancing the advantages of pesticides by modulating properties, such as stability and solubility. Triflumezopyrim is a crucial insecticide for managing ...

Chiral resolution by crystallization is a highly scalable and economically viable technique crucial for the pharmaceutical industry. While the use of multicomponent crystals, such as salts and ...

The 15 percent tariff rate agreed under the new deal could significantly impact pharma firms reliant on European imports.

TOKYO (Reuters) -Japan's leading trade negotiator said on Tuesday that the trade deal Tokyo agreed with the United States last week guarantees Japan will always receive the lowest tariff rate on ...

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts ...

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. | After ...